OverviewChartNewsTraderScreen

Vaxart/  US92243A2006  /

IEX
21/05/2024  21:59:10 Chg. -0.04 Volume Bid- Ask- High Low
0.86USD -4.10% 3,793
Turnover: 3,247.91		 -Bid Size: - -Ask Size: - 0.89 0.85
GlobeNewswire 13/05 Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire 07/05 Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
GlobeNewswire 30/04 Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire 27/03 Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
GlobeNewswire 20/03 Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 14/03 Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
GlobeNewswire 07/03 Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
GlobeNewswire 06/03 Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
GlobeNewswire 05/02 Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Nex...
GlobeNewswire 19/01 Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Eva...
GlobeNewswire 16/01 Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
GlobeNewswire 16/01 Vaxart, Inc. Announces Management Change
GlobeNewswire 21/12/2023 Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating...
GlobeNewswire 02/11/2023 Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire 02/11/2023 Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
GlobeNewswire 26/10/2023 Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November ...
GlobeNewswire 11/10/2023 Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
GlobeNewswire 21/09/2023 Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
GlobeNewswire 06/09/2023 Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine C...
TeleTrader 06/06/2023 Vaxart commences public offering of common stock
TeleTrader 01/09/2022 Vaxart jumps 10% on pill COVID vaccine results
GlobeNewswire 24/02/2022 Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire 14/02/2022 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
GlobeNewswire 04/01/2022 Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference
GlobeNewswire 16/12/2021 Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron